A new study suggests the high-dose flu vaccine, already recommended for older adults, may lower Alzheimer’s risk by roughly 15% to 20% compared to the standard shot — a finding that complicates earlier hopes of a much larger protective effect.
The research, published this month in Neurology, analyzed health records of about 165,000 adults aged 65 and older who received either the high-dose or standard influenza vaccine between 2014 and 2019. Researchers at UTHealth Houston followed them for approximately three years post-vaccination, finding that those who got the high-dose formulation — which contains four times the antigen of the standard vaccine — had a measurably lower incidence of Alzheimer’s diagnosis over the follow-up period.
This builds on earlier work by the same team, including a 2022 study that linked regular flu vaccination to up to a 40% reduction in Alzheimer’s risk over six annual shots. But that earlier finding raised concerns about the “healthy vaccinee effect” — the possibility that people who get vaccinated simply tend to lead healthier lives making it hard to isolate the vaccine’s direct impact.
To address that, the current study compared only vaccinated individuals, splitting them by dose. Even within this group, the high-dose version showed a relative benefit, suggesting the effect may not be entirely explained by lifestyle differences. Still, the magnitude of protection is more modest than the 55% risk reduction highlighted in some headlines — a figure that appears to conflate or overstate the study’s actual results.
Dr. Paul Schulz, the study’s lead author and a neurologist at McGovern Medical School, noted the finding emerged almost by chance. After giving a talk at the Houston Public Health Department, he learned that not all older adults consistently receive the high-dose vaccine despite CDC recommendations, often due to supply shortages. That variability created a natural experiment: “That led to the paper,” he told Medical News Today, “where the goal was to test whether, when we enrolled only people who were vaccinated [whether with a high or low dose], there was still a protective effect.”
For more on this story, see High-Dose Flu Vaccine Linked to Lower Alzheimer’s Risk in Older Adults.
The study does not prove causation, and experts caution against getting the high-dose flu shot solely for brain health. “The findings are limited, and experts say it’s too soon to recommend the high-dose shot for this purpose alone,” the San Francisco Chronicle reported, echoing Schulz’s own restraint. Instead, the work adds to a growing body of research suggesting certain vaccines — particularly the shingles vaccine — may influence dementia risk through mechanisms beyond infection prevention.
One leading hypothesis involves inflammation. Both influenza and shingles can trigger neuroinflammatory responses, which are increasingly implicated in Alzheimer’s pathology. By modulating the immune system, vaccines might indirectly calm chronic brain inflammation. As Schulz position it: “The vaccination turns on your ability to craft antibodies against the virus. But we think as a side effect, the activity in the arm has a modulating effect on the brain, on inflammatory cells.”
This follows our earlier report, High-Dose Flu Vaccine Linked to Lower Alzheimer’s Risk in Seniors.
This line of inquiry reflects a broader shift in dementia research: moving beyond amyloid plaques and tau tangles to consider how systemic immune health shapes brain aging. If future studies confirm these links, routine vaccinations could become an unexpected tool in public health strategy — not just for preventing flu or shingles, but for preserving cognitive resilience in older populations.
Is the high-dose flu vaccine now recommended specifically to prevent Alzheimer’s?
No. Health experts, including the study’s lead author, emphasize that the high-dose flu vaccine should still be obtained primarily for its proven protection against influenza, especially in adults 65 and older. The potential link to lower Alzheimer’s risk remains observational and preliminary; it is not sufficient to change current vaccination guidelines.
How does the high-dose flu vaccine differ from the standard version?
The high-dose influenza vaccine contains four times the amount of antigen — the component that stimulates an immune response — compared to the standard-dose vaccine. It is specifically formulated for older adults because aging weakens immune function, and the higher dose helps generate a stronger antibody response to counteract this decline.
Worth a look
